innovations that make RNAi therapeutics possible. Nearly 15 years of R&D work delivered the world’s first approved RNAi therapeutic—ONPATTRO® (patisiran)—in 2018 and, subsequently, GIVLAARI® (givosiran), OXLUMO® (lumasiran), Leqvio® (inclisiran)*, and AMVUTTRA® (vutrisiran)....
innovations that make RNAi therapeutics possible. Nearly 15 years of R&D work delivered the world’s first approved RNAi therapeutic—ONPATTRO® (patisiran)—in 2018 and, subsequently, GIVLAARI® (givosiran), OXLUMO® (lumasiran), Leqvio® (inclisiran)*, and AMVUTTRA® (vutrisiran)....
PCKS9 Inhibitors (evolocumab, alirocumab, and inclisiran):PCSK9 inhibitors have been shown to be highly effective in lowering LDL-C (a type of harmful cholesterol) when used in addition to statins. Praluent (alirocumab) and Repatha (evolocumab) are injections that can be given at home but...